257 related articles for article (PubMed ID: 38740566)
1. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
Milder DA; Milder TY; Liang SS; Kam PCA
Anaesthesia; 2024 Jul; 79(7):735-747. PubMed ID: 38740566
[TBL] [Abstract][Full Text] [Related]
2. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration.
van Zuylen ML; Siegelaar SE; Plummer MP; Deane AM; Hermanides J; Hulst AH
Br J Anaesth; 2024 Apr; 132(4):644-648. PubMed ID: 38290907
[TBL] [Abstract][Full Text] [Related]
3. Perioperative management of patients on glucagon-like peptide-1 receptor agonists.
Mizubuti GB; Ho AM; Silva LMD; Phelan R
Curr Opin Anaesthesiol; 2024 Jun; 37(3):323-333. PubMed ID: 38390914
[TBL] [Abstract][Full Text] [Related]
4. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.
Garza K; Aminpour E; Shah J; Mehta B; Early D; Gyawali CP; Kushnir V
Am J Gastroenterol; 2024 Jun; 119(6):1081-1088. PubMed ID: 38534127
[TBL] [Abstract][Full Text] [Related]
6. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
[TBL] [Abstract][Full Text] [Related]
7. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management.
Hiramoto B; McCarty TR; Lodhia NA; Jenkins A; Elnaiem A; Muftah M; Flanagan R; Chan WW
Am J Gastroenterol; 2024 Jun; 119(6):1126-1140. PubMed ID: 38634551
[TBL] [Abstract][Full Text] [Related]
8. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
10. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
Camafort-Babkowski M
Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
[TBL] [Abstract][Full Text] [Related]
11. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
Maselli DB; Camilleri M
Adv Exp Med Biol; 2021; 1307():171-192. PubMed ID: 32077010
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know.
Chan PYW; Mika AP; Martin JR; Wilson JM
JBJS Rev; 2024 Jan; 12(1):. PubMed ID: 38181103
[TBL] [Abstract][Full Text] [Related]
13. Point-of-Care Gastric Ultrasound to Identify a Full Stomach on a Diabetic Patient Taking a Glucagon-Like Peptide 1 Receptor Agonist.
Girón-Arango L; Perlas A
A A Pract; 2024 Feb; 18(2):e01751. PubMed ID: 38305719
[TBL] [Abstract][Full Text] [Related]
14. Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists.
Raven LM; Brown C; Greenfield JR
Med J Aust; 2024 Jan; 220(1):14-16. PubMed ID: 38009941
[No Abstract] [Full Text] [Related]
15. Glucagon-like peptide analogues for type 2 diabetes mellitus.
Shyangdan DS; Royle P; Clar C; Sharma P; Waugh N; Snaith A
Cochrane Database Syst Rev; 2011 Oct; 2011(10):CD006423. PubMed ID: 21975753
[TBL] [Abstract][Full Text] [Related]
16. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report.
Gulak MA; Murphy P
Can J Anaesth; 2023 Aug; 70(8):1397-1400. PubMed ID: 37280458
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.
Klen J; Dolžan V
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408810
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Cahen DL; van Raalte DH
Diabetes Obes Metab; 2016 Mar; 18(3):224-35. PubMed ID: 26500045
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
[TBL] [Abstract][Full Text] [Related]
20. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
Herrou J; Mabilleau G; Lecerf JM; Thomas T; Biver E; Paccou J
Calcif Tissue Int; 2024 Feb; 114(2):86-97. PubMed ID: 37999750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
